tofacitinib oral IBD
Selected indexed studies
- Ulcerative Colitis in Adults: A Review. (JAMA, 2023) [PMID:37698559]
- Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease. (Cytokine Growth Factor Rev, 2024) [PMID:39179485]
- Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. (Pharmacoeconomics, 2023) [PMID:36884164]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. (2023) pubmed
- Ulcerative Colitis in Adults: A Review. (2023) pubmed
- Tofacitinib experience in patients with enteropathic arthritis. (2023) pubmed
- Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease. (2024) pubmed
- Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. (2023) pubmed
- Real-World Experience with Tofacitinib in IBD at a Tertiary Center. (2019) pubmed
- The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review. (2025) pubmed
- Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis. (2021) pubmed
- Safety and Effectiveness of Thiopurines and Small Molecules in Elderly Patients with Inflammatory Bowel Diseases. (2024) pubmed
- The Role of Novel Small Molecule Drugs in the Management of Inflammatory Bowel Disease. (2025) pubmed